Eli Lilly (LLY)

Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate.

There's a new challenger to the more established players in the weight-loss drug space.

Can Novo Nordisk thrive under intense competitive pressures?

Healthcare is booming, and these three companies stand to profit handsomely from growing demand for medications and surgeries.

The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player closely.

Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market.

Amphastar Pharmaceuticals (NASDAQ:AMPH) executives said the company is taking steps to address rebate and discounting pressure on BAQSIMI while maintaining its full-year revenue outlook, according to remarks at the BofA Annual Healthcare Conference. Bill Peters, chief financial officer of Amphastar

William Blair gives Kailera Therapeutics ($KLRA) an Outperform rating. Learn why analysts see a competitive edge in their GLP-1 assets.

The worst might be in the rearview mirror.

Eli Lilly data shows patients maintain weight loss with Foundayo or lower-dose Zepbound after switching from injectable therapies.

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a...

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.4% in the afternoon session after the stock continued to rally as the co...

Hims & Hers is unshaken by its earnings miss, with management promising even faster sales growth this year.

Analysts initiated covered Tuesday of IPO stock, a potential competitor to Lilly and Novo in obesity.

These growth stocks are benefiting from major tailwinds across cloud computing, digital payments, and healthcare.

It's important to look beyond near-term volatility.

The weight loss drug market is on track to reach almost $100 billion.

GoodRx (GDRX) Q1 2026 Earnings Call Transcript

Omada Health (OMDA) Q1 2026 Earnings Transcript

The competition is far behind.

Omada Health (NASDAQ:OMDA) reported what executives described as a “milestone quarter” for the first quarter of 2026, highlighting 42% year-over-year revenue growth, expanding margins, and positive adjusted EBITDA alongside a raised full-year outlook. On the earnings call, Co-Founder and CEO Sean D

Eli Lilly's next obesity drug, retatrutide, is so popular it's already getting copied. Can Lilly compete with its own drug?